About Gamma-aminobutyric acid receptor subunit epsilon
Gamma-aminobutyric acid receptor subunit epsilon (GABRE) is a protein
from Homo sapiens identified by UniProt accession
P78334, 506 residues long.
MolForge cross-references it against 0 known binders and
303 disease associations.
Target properties
| Protein name | Gamma-aminobutyric acid receptor subunit epsilon |
| UniProt accession | P78334 |
| Gene | GABRE |
| Organism | Homo sapiens |
| Length | 506 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (303)
Diseases linked to this target (Open Targets).
- epilepsy · score 0.61
- migraine disorder · score 0.60
- pain · score 0.60
- alcohol dependence · score 0.59
- delirium · score 0.59
- obesity · score 0.58
- coronary artery disease · score 0.58
- Seizure · score 0.58
- Agitation · score 0.57
- depressive disorder · score 0.57
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P78334-F1 | alphafold | PREDICTED | 72.53 | — |
Amino-acid sequence (506 residues)
MLSKVLPVLL GILLILQSRV EGPQTESKNE ASSRDVVYGP QPQPLENQLL SEETKSTETE TGSRVGKLPE ASRILNTILS NYDHKLRPGI GEKPTVVTVE ISVNSLGPLS ILDMEYTIDI IFSQTWYDER LCYNDTFESL VLNGNVVSQL WIPDTFFRNS KRTHEHEITM PNQMVRIYKD GKVLYTIRMT IDAGCSLHML RFPMDSHSCP LSFSSFSYPE NEMIYKWENF KLEINEKNSW KLFQFDFTGV SNKTEIITTP VGDFMVMTIF FNVSRRFGYV AFQNYVPSSV TTMLSWVSFW IKTESAPART SLGITSVLTM TTLGTFSRKN FPRVSYITAL DFYIAICFVF CFCALLEFAV LNFLIYNQTK AHASPKLRHP RINSRAHART RARSRACARQ HQEAFVCQIV TTEGSDGEER PSCSAQQPPS PGSPEGPRSL CSKLACCEWC KRFKKYFCMV PDCEGSTWQQ GRLCIHVYRL DNYSRVVFPV TFFFFNVLYW LVCLNL
Explore Gamma-aminobutyric acid receptor subunit epsilon with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets